B. Riley Securities Reiterates Buy on Novavax, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has reiterated its Buy rating on Novavax and increased the price target from $23 to $26, indicating confidence in the company's future performance.
October 10, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities has reiterated its Buy rating on Novavax and increased the price target from $23 to $26, suggesting a positive outlook for the company's stock.
The reiteration of a Buy rating and an increased price target by a reputable analyst firm like B. Riley Securities is likely to boost investor confidence in Novavax, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100